Mutation analysis of CBP and PCAF reveals rare inactivating mutations in cancer cell lines but not in primary tumors.

MLA

Ozdag, H., et al. “Mutation Analysis of CBP and PCAF Reveals Rare Inactivating Mutations in Cancer Cell Lines but Not in Primary Tumors.” British Journal of Cancer, vol. 87, no. 10, Nov. 2002, p. 1162. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=8666528&authtype=sso&custid=ns315887.

APA

Ozdag, H., Batley, S. J., Forsti, A., Iyer, N. G., Daigo, Y., Boutell, J., Arends, M. J., Ponder, B. A. J., Kouzarides, T., & Caldas, C. (2002). Mutation analysis of CBP and PCAF reveals rare inactivating mutations in cancer cell lines but not in primary tumors. British Journal of Cancer, 87(10), 1162.

Chicago

Ozdag, H., S.J. Batley, A. Forsti, N.G. Iyer, Y. Daigo, J. Boutell, M.J. Arends, B.A.J. Ponder, T. Kouzarides, and C. Caldas. 2002. “Mutation Analysis of CBP and PCAF Reveals Rare Inactivating Mutations in Cancer Cell Lines but Not in Primary Tumors.” British Journal of Cancer 87 (10): 1162. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=8666528&authtype=sso&custid=ns315887.